The popularity of traditional cigarettes has been in decline for years, but Altria's (NYSE: MO) dividend continues to rise as the company diversifies into new vices. The days of the Marlboro Man and product placement in "cool" movie scenes are mostly gone - so Altria has shifted much of its attention to vaping and even marijuana. But Altria still controls Philip Morris USA, and it makes a significant portion of its revenue from traditional tobacco products. This revenue stream is reliable due to the difficulties of quitting tobacco - even in the face of higher tobacco taxes, strict advertising controls and younger demographics avoiding the substance. And in 2018, Altria looked to pick up the slack from some of these challenges with a massive $12.8 billion (35%) investment in electronic cigarette manufacturer Juul Labs. This deal has been controversial from the start because of monopoly concerns. This past April, the Federal Trade Commission even filed an antitrust lawsuit against Altria. It will take time to resolve, but in January, Altria took a $4.1 billion write-down of its Juul investment due to the increasing number of lawsuits it faced. Some of the lawsuits focused on vaping-related lung illnesses, and some contended that young people have been targeted by deceptive marketing. Also in 2018, Altria bought 45% of Canadian marijuana company Cronos Group (Nasdaq: CRON) for $1.8 billion. This investment has yet to be profitable, as the overall cannabis industry has declined after a much-hyped beginning just a few years ago. Do these hurdles mean Altria's dividend is in trouble? |
No comments:
Post a Comment